Luminar Media Group recently announced that, after completing development of a working prototype device, the Jenex Corporation has signed an agreement with the Techna Institute at the University Health Network to begin testing the TherOZap™ device’s efficacy against the West Nile and Zika viruses.
The Jenex Corporation describes itself as a progressive medical technology company involved in the creation of an array of dermatological medical device products. Aside from TherOZap™, Jenex’s website indicates that it currently markets the Intercept CS device which is said to prevent cold sore outbreaks using the device’s thermal heat conductivity.
Jenex and the Techna Institute are developing a series of protocols for the initial testing of the TherOZap™ device. Regarding the current stage of development of the device, Rob Fia, CEO of the Jenex Corporation, stated:
We are pleased to test our patent pending TherOZap™ technology against both the Zika and West Nile virus’ especially given the wide spread of the Zika virus around the world. Jenex has engaged a world-renowned lab to initiate testing of the technology to determine if it can be effective in inactivating the virus. We look forward to providing an update on the initial results of the tests in the near future.